Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, calls, and what-not has, of course, returned. You knew this would happen, yes? There is only one thing we can do under such circumstances and that is to fire up the coffee kettle to brew some cups of stimulation. Our choice this morning is almond toffee. Sounds tempting, yes? Well, either way, here are some tidbits to keep you focused. Hope your day goes well and do keep in touch …

Novartis (NVS) is exploring working with the global reinsurance industry to help health systems bear the cost of a new generation of personalized therapies as the industry comes under pressure to devise funding models for ultra-expensive medicines, The Financial Times reports. The drug maker is “brainstorming” alternative financing possibilities for drugs that offer the prospect of curing patients of once-fatal diseases, potentially saving substantial healthcare costs down the line — but requiring enormous upfront outlays.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy